{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012519","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2022-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.533731+00:00","generated_at":"2026-06-24T19:16:35.709809+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Myomo pre-announces Q2 revenue $3.4-3.6M, up 10-16% YoY; record pipeline adds","bullets":["Preliminary Q2 2022 revenue $3.4–$3.6M, up 10–16% vs Q2 2021; all product revenue.","Added >400 prospective MyoPro patients in Q2, a quarterly record; cost per pipeline add decreased.","Second JV license fee payment from China partner delayed due to COVID-19 banking/government backlog.","Participated in CMS public hearing for Benefit Category Determination to reclassify MyoPro as custom-fabricated brace.","Full Q2 results and conference call scheduled for August 3, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012519","json":"https://secwatch.observer/filing/0000950170-22-012519.json","markdown":"https://secwatch.observer/filing/0000950170-22-012519.md","text":"https://secwatch.observer/filing/0000950170-22-012519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017022012519/0000950170-22-012519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017022012519/myo-20220707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T19:16:35.709809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}